compound 16a

Compound 16a is a synthetic thiazolobenzimidazole-thiazole hybrid identified as a potent inhibitor of colon cancer. It was developed as part of a series of novel hybrids evaluated against the HCT-116 colon carcinoma cell line, where it demonstrated significant cytotoxicity with an IC50 value of less than 7.1 μM. Molecular docking studies indicate that the compound targets the kinesin-like protein KIF11 (also known as Eg5), a protein essential for mitosis, by interacting with the binding site identified in the PDB structure 6MTU. The compound is predicted to have high oral absorption (up to 100%) and favorable ADMET properties, including a lack of predicted skin sensitization toxicity, making it a lead candidate for further preclinical investigation in the treatment of colorectal malignancies.